Compounded Peptides: What to Check Before You Buy
This is the one category on this site where we do not publish a ranked list of providers, and the reason is the point of the page. As of August 2026, none of the research peptides people want compounded (BPC-157, TB-500, MOTS-c, KPV, semax, epitalon) may legally be compounded in the United States. They came off the FDA's restricted Category 2 list in April 2026, which removed a prohibition without granting permission, and an advisory committee recommended six of them in July, which is advice rather than law. The rulemaking that would actually change this has not happened. Pharmacies are taking orders anyway, so what follows is the enforcement record and the questions worth asking, rather than a leaderboard.
Honest context
We will list and score providers in this category when the FDA completes rulemaking and these substances are genuinely compoundable, and not before. Publishing a ranked list today would imply a legitimacy the legal position does not support, and it would be worth money to the companies in it, which is exactly the conflict our vetting methodology exists to avoid. If you intend to proceed regardless, the criteria below are the ones that separate a serious pharmacy from a risky one.
All Peptide compounding providers, ranked
Ranked by our overall 0-5 score, weighted across the same six dimensions on every provider profile. Scores update after every quarterly review.
No providers published in this category yet. Check back soon.
What to look for in Peptide compounding
The criteria that actually matter when comparing providers in this category, beyond headline pricing.
01FDA enforcement history, searched under the legal entity name
This is the check almost nobody runs and the one that separates the field. Empower Pharmacy (Empower Clinic Services, LLC) received a warning letter dated 15 October 2021 after a February to March 2020 inspection of its Houston facility, where the FDA found drug products that failed to meet the conditions of section 503B. Tailor Made Compounding received one dated 1 April 2020 in which investigators noted, verbatim, "serious deficiencies in your practices for producing sterile drug products, which put patients at risk", and which also records the company's voluntary recall of tesamorelin produced between July and September 2018 over an incorrect beyond-use date on the vial labels. These letters are historical and firms do remediate; we could not confirm from the FDA's close-out records whether either has been formally closed out. The point is not that these companies are uniquely bad. It is that the biggest names in the category have documented findings, the documents are public and free, and the marketing will never mention them.
02Whether you are buying from a 503A pharmacy or a 503B outsourcing facility
These are different legal animals and the difference changes what protections you have. A 503A pharmacy compounds against an individual prescription and is exempt from current good manufacturing practice requirements. A 503B outsourcing facility may compound in bulk without patient-specific prescriptions but must follow CGMP and register with the FDA. Tailor Made's 2020 letter was issued under 503A; Empower's 2021 letter was issued under 503B, against a facility that had been registered as an outsourcing facility since 2016. Ask which one is filling your order, and note that a company can run both.
03Whether they will tell you the substance is not on the permitted list
A pharmacy that is straight with you about the legal position is telling you something about the rest of its conduct. The honest framing is that these substances sit in a gap: off the restricted list, not on the permitted one, pending rulemaking. A vendor that tells you the FDA approved or legalized these peptides in April 2026 is either misinformed about its own regulatory environment or willing to say things that are not true, and neither is what you want from someone making a sterile injectable.
04A certificate of analysis you can trace to a named third-party lab
A COA on the pharmacy's own letterhead is a claim, not a check. You want the testing lab named, the method stated (HPLC for purity, mass spectrometry for identity), a lot number that matches your vial, and a date. Ask whether identity was tested on the finished product or only on the incoming raw material, because those are different assurances. Worth remembering that at the July 2026 advisory meeting an FDA official said of these compounds, on the record, "We've never faced a problem of, 'What is it?'", which is a striking admission about how hard identity is to establish here.
05Sterile compounding practice and USP 797 compliance
Every warning letter above turns on sterility. This is the failure mode that actually hurts people, well before any question of whether a peptide works. Look for USP 797 compliance, a stated beyond-use-date policy, and ideally PCAB accreditation, which is voluntary and therefore a real signal rather than table stakes. The Tailor Made recall was specifically a beyond-use-date labelling failure: quiet, unglamorous, and it reached patients.
06A named prescriber relationship rather than a checkout button
Compounded medicines require a prescription from a clinician who has actually evaluated you. If a site will sell you an injectable peptide on a form and a card, it is not operating the way the rules contemplate, whatever the footer says. That model is also the most exposed if the FDA declines to add these substances to the 503A list.
Frequently asked
The questions readers actually have about Peptide compounding providers.
Can a compounding pharmacy legally sell me BPC-157 right now?
No. BPC-157 is not FDA-approved, has no USP monograph, is not a component of an approved drug, and is not on the 503A bulk drug substances list. Those are the routes by which a substance qualifies for compounding and it meets none of them. Coming off Category 2 in April 2026 removed an explicit prohibition; it did not create permission. The July 2026 advisory vote recommended adding it, but that recommendation is non-binding and the FDA has not completed the rulemaking that would make it real.
Why does this page not rank providers like the other categories?
Because ranking implies a recommendation, and we are not in a position to recommend buying something that cannot lawfully be sold. Our other category pages compare providers on price, service and record inside a legal market. This is not a legal market yet. When the FDA completes rulemaking we will apply the same six-dimension rubric here that we apply everywhere else, and publish the scores with their reasoning.
How do I check a pharmacy for FDA warning letters myself?
Search the FDA warning letter database for the company's legal entity name, which is usually in the terms of service or privacy policy rather than the marketing. Also check the FDA's compounding inspections and recalls page, which lists Form 483 observations and recalls separately from warning letters. Both are free and public. A finding from several years ago is not automatically disqualifying, since firms do remediate, but you want to know it exists and to hear what the company says when asked about it.
Is a 503B outsourcing facility safer than a 503A pharmacy?
In principle yes, because 503B facilities must comply with current good manufacturing practice requirements and register with the FDA, while 503A pharmacies are exempt from CGMP. In practice registration is not a guarantee: Empower's October 2021 warning letter was issued against a registered 503B outsourcing facility. Treat the designation as a floor worth having rather than a verdict.
What happens to compounded peptides if the FDA says no?
They stay where they are now, outside the lawful compounding pathway, and the enforcement risk for pharmacies selling them rises rather than falls. The FDA is not obliged to follow its advisory committee, and at the July 2026 meeting that committee voted against the agency's own scientists. A favourable outcome is likely but not assured, and the companies building inventory ahead of it are making a commercial bet, not following a settled rule.
Related reading
Where else to look on the site for context on this category.
The peptide evidence matrix
Before asking where to buy one, it is worth seeing how many of these have human evidence behind them.
How we vet providers
The six-dimension rubric we will apply here once this is a legal market.
Peptide safety
Sterility, dosing and contamination risk, which is what the enforcement record is really about.
All peptides
The full catalogue, with regulatory status on every entry.
Spot something out of date or wrong? Let us know.
Back to provider directory